Am Fam Physician. 2022;105(4):438-439
Author disclosure: No relevant financial relationships.
Key Points for Practice
• Prediabetes is not a diagnosis but rather an opportunity to prevent or delay a future diagnosis of type 2 diabetes.
• Intensive lifestyle programs are the most effective intervention for preventing or delaying a diagnosis of diabetes in patients with prediabetes.
• In patients with prediabetes, metformin therapy will slow the progression to type 2 diabetes, although less effectively than lifestyle programs over time.
• In patients who have had gestational diabetes, the benefits of metformin therapy are similar to those of lifestyle programs.
From the AFP Editors
Screening high-risk individuals for diabetes mellitus is essential because approximately one-fourth of Americans with diabetes are undiagnosed. The American Diabetes Association (ADA) recommends screening all adults 45 years and older for diabetes every three years using A1C, fasting glucose, or two-hour glucose tolerance testing. People younger than 45 years who are overweight or obese and are at high risk because of a family history, certain medical conditions (e.g., cardiovascular disease, hypertension, dyslipidemia, polycystic ovary syndrome), or physical inactivity and those who belong to a high-risk racial or ethnic group (i.e., African American, Latino, Native American, Asian American, and Pacific Islander) or who have signs of insulin resistance (e.g., severe obesity, acanthosis nigrans, small-for-gestational age birth weight) should also receive regular testing.
Classifying screening test results as indicative of prediabetes shows an increased risk of a future diagnosis of type 2 diabetes and provides an opportunity for prevention. Criteria for prediabetes, including A1C levels of 5.7 to 6.4, fasting plasma glucose of 100 to 125 mg per dL (5.55 to 6.94 mmol per L), or two-hour glucose of 140 to 199 mg per dL (7.77 to 11.04 mmol per L) after a 75-mg oral glucose load, identify individuals for whom diabetes prevention will be beneficial. The ADA has released updated guidelines for the prevention or delay of diabetes.
Strong evidence supports lifestyle interventions to delay or prevent diabetes. Programs that include diet, weight loss, and exercise reduce type 2 diabetes diagnoses by up to 58% over three years. Over longer periods, 27% to 43% of people will avoid a diagnosis of diabetes with sustained lifestyle changes.
Programs should be modeled after the National Diabetes Prevention Program, which targets sustained weight loss of at least 7% of body weight and at least 150 minutes of moderate-intensity exercise weekly. Although weight loss is considered the most important factor for lowering the risk of type 2 diabetes, achieving the physical activity goal of at least 150 minutes per week can reduce diabetes incidence by 44% without weight loss.
Because no optimal diet has been identified to prevent the onset of diabetes, dietary counseling should be tailored to individual preferences. A Mediterranean-style or low-carbohydrate diet, and perhaps a vegetarian, plant-based, or Dietary Approaches to Stop Hypertension (DASH) diet, can reduce the risk of developing type 2 diabetes.
The National Diabetes Prevention Program brings evidence-based lifestyle change programs into communities. Overweight, nonpregnant adults with prediabetes can be referred to the program by their physician, or patients may self-refer (https://www.cdc.gov/diabetes/prevention/find-a-program.html).
Medications can delay or prevent type 2 diabetes but are less effective than lifestyle programs. Metformin has the strongest evidence, whereas liraglutide, insulin, thiazolidinediones, alpha-glucosidase inhibitors, orlistat (Xenical), and phentermine/topiramate (Qsymia) all have some evidence of benefit. Initially, metformin is nearly as effective as lifestyle modification; however, over time, lifestyle interventions demonstrate clear superiority. In patients with previous gestational diabetes, metformin reduces diabetes incidence by 50%, equivalent to lifestyle changes. Because long-term use of metformin can lead to vitamin B12 deficiency, monitoring vitamin B12 levels should be considered.
Because diabetes increases cardiovascular risk, identifying prediabetes provides an opportunity to reduce that risk. Treating hypertension, dyslipidemia, and tobacco dependence should be considered. Because smoking cessation can increase diabetes risk for several years, tobacco cessation should be combined with diabetes prevention.
Although evidence is limited, annual laboratory monitoring is recommended for patients with prediabetes to track treatment effectiveness and the development of type 2 diabetes.
Guideline source: American Diabetes Association
Evidence rating system used? Yes
Systematic literature search described? Yes
Guideline developed by participants without relevant financial ties to industry? No
Recommendations based on patient-oriented outcomes? No
Published source: Diabetes Care. September 2021;44(suppl 1) S34–S39
Available at: https://doi.org/10.2337/dc21-S003
Editor’s Note: Prediabetes is controversial because it describes a population at increased risk rather than a current or future diagnosis or any definitive harm. We must decide what to do with the opportunity for prevention from borderline laboratory results. These ADA recommendations support and add to recent recommendations from the U.S. Preventive Services Task Force (USPSTF; https://www.aafp.org/afp/2022/0100/od1.html). Although the USPSTF recommends regular diabetes screening for adults 35 to 70 years of age who are overweight or obese, the ADA recommends screening all adults 45 years and older, as well as any adult who is overweight or obese and has one or more additional risk factors. Race is included as a risk factor by the ADA, although it is a social construct that may not represent a genetic predisposition. The USPSTF and ADA suggest three-year screening intervals and lifestyle interventions, metformin, or both for patients with prediabetes. This ADA guideline adds more specifics to these recommendations.—Michael J. Arnold, MD, Contributing Editor
Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP.
This series is coordinated by Michael J. Arnold, MD, contributing editor.
A collection of Practice Guidelines published in AFP is available at https://www.aafp.org/afp/practguide.
Copyright © 2022 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.
Copyright © 2022 American Academy of Family Physicians. All Rights Reserved.
